Marstacimab 150mg/1ml solution for injection pre-filled disposable devices
Requires a prescription from a doctor or prescriber
Antifibrinolytic drugs and haemostatics
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Marstacimab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Marstacimab on the MHRA register
Hympavzi 150mg/1ml solution for injection pre-filled pens
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Marstacimab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
26.025 hours
Mechanism
TFPI is a serine protease and primary inhibitor of the extrinsic coagulation pathway.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
71%
Half-life
26.025 hours
Volume of distribution
8.6 L
[L51803]
Metabolism
[L51803]
Elimination
90%
Clearance
0.06595 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
- hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or [L51803]
- hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
[L51803]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 379 interactions
Hemophilia A and B are hereditary bleeding disorders associated with deficiencies in coagulation clotting factors VIII (FVIII) and IX (FIX), respectively, of the intrinsic coagulation pathway.[A264613][A264618] Marstacimab is a human monoclonal IgG1 antibody directed against the K2 to neutralize TFPI.[L51803] Even in the absence of FVIII or FIX, marstacimab-induced inhibition of TFPI leads to increased generation of FXa and, ultimately, thrombin production and clot formation.[A264618]
Marstacimab increases the total TFPI (indicating both free TFPI and marstacimab-bound TFPI) and downstream biomarkers of thrombin generation such as prothrombin fragments 1+2, peak thrombin, and D-Dimer in patients with hemophilia. These changes were observed and persisted over a 7-day period following a single subcutaneous dose and were reversible after treatment discontinuation.[L51803]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L51803]
The steady-state Cmin and Cmax were calculated in adult and adolescent patients weighing at least 35 kg. Patients received a once-weekly subcutaneous dose of 150 mg.
The mean Cmin (%CV) were 13.7 (90.4%) mcg/mL and 27.3 (53.2%) mcg/mL in adults and adolescents, respectively. The mean Cmax (%CV) were 17.9 (77.5%) mcg/mL and 34.7 (48.5%) mcg/mL in adults and adolescents, respectively.
[L51803]
In a study consisting of Chinese patients with severe hemophilia, the AUCinf was 4549 μg x h/mL following a single subcutaneous 300 mg dose.
[A264598]
[A264598]
The median time for 50% of marstacimab to be eliminated is approximately seven to 10 days.
[L51803]
[L51803]
[L51803]
[L51803]
Based on population pharmacokinetic analysis, about 90% of marstacimab is expected to be eliminated by the end of approximately one month after the last dose.
[L51803]
[A264598]
Marstacimab clearance (CL) was 29% lower in adolescents (12 to <18 years of age) compared to adults (18 years and older). No clinically significant difference in adolescent marstacimab CL (L/hr/kg) compared to adults was observed after adjusting for body weight.
[L51803]
Proteins and enzymes this drug interacts with in the body
ATC B02BX11
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Marstacimab
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: